The emergence of the Cicada COVID-19 variant has raised significant concern globally, particularly as it has now been detected in India. This variant, classified as BA.3.2, is an offshoot of the Omicron family tree, indicating it is not a completely new threat but rather a continuation of the ongoing battle against COVID-19.

First spotted in South Africa in November 2024, the Cicada variant carries around 75 mutations, with over 50 of these located in the spike protein. This extensive mutation profile has led to increased scrutiny from health authorities worldwide.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. While these symptoms are concerning, it is important to note that the Cicada variant is not confirmed to cause more severe illness than previous variants.

As of now, the variant has been detected in 22 countries, including India, which has prompted health officials to monitor its spread closely. The first confirmed case of the Cicada variant in the United States was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered.

Dr. Robert Hopkins Jr. has stated, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the uncertainty surrounding the variant’s potential impact on public health.

The Centers for Disease Control and Prevention (CDC) emphasized the importance of monitoring the spread of BA.3.2, noting that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.

Details remain unconfirmed regarding the real-world data on the severity of illness caused by the Cicada variant. As health authorities continue to gather information, the situation remains fluid.

In conclusion, the detection of the Cicada variant in India underscores the ongoing challenges posed by COVID-19 and the need for vigilance in monitoring and responding to new variants as they emerge.

The post Cicada COVID Variant in India: Latest Developments appeared first on newsrush.

The cicada COVID variant, officially designated as BA.3.2, is causing significant concern among health officials due to its potential to evade immunity from vaccines and previous infections. As of February 2026, this heavily mutated variant has been detected in at least 25 states across the United States, raising alarms about its spread and impact on public health.

First identified in South Africa in November 2024, BA.3.2 has since been classified as a ‘variant under monitoring’ by the World Health Organization (WHO) since December 2025. The variant is characterized by an alarming 70 to 75 mutations in its spike protein, which may significantly reduce the effectiveness of existing vaccines against infection, though they are still expected to provide protection against severe disease.

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues. Despite its rapid spread, experts have noted that BA.3.2 is not currently causing more severe disease or hospitalizations compared to previous strains. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.”

The variant’s unusual emergence pattern has led to its nickname, ‘cicada’, drawing a parallel to the lifecycle of the insect. This nomenclature reflects the variant’s sudden appearance and potential for resurgence, similar to the periodic emergence of cicadas in nature.

As of February 11, 2026, BA.3.2 has been detected in at least 23 countries, with a notable presence in Denmark, Germany, and the Netherlands, where it accounts for approximately 30% of cases. In the U.S., about 3.7% of sewage samples nationwide have shown the presence of BA.3.2, indicating its growing prevalence.

Experts like Andrew Pekosz, Ph.D., have expressed concerns about the variant’s mutations, stating, “It has a lot of mutations that may cause it to look different to your immune system.” This raises questions about the long-term efficacy of current vaccines. However, vaccination remains a crucial tool in limiting cases and preventing severe outcomes.

Despite the challenges posed by BA.3.2, the exact reasons for its resurgence remain unclear, and the long-term impact on public health is uncertain. As health authorities continue to monitor the situation, further developments are expected in the ongoing battle against COVID-19.

The post Cicada COVID Variant: The Emergence of BA.3.2 appeared first on newsrush.